A Single Bench of Hon'ble Delhi High Court vide its order
dated April 20, 2021, granted an ex-parte ad-interim injunction in
favour of the Plaintiff Mankind Pharma Limited and the Defendant
Novakind Bio Sciences Private Limited, restraining the company from
further manufacturing, either on its own behalf or through any job
worker, marketing or clearing for sale in the market any
pharmaceutical product bearing the 'KIND' suffix or which
may in any manner infringe the registered trademarks of the
Plaintiff.
SUBMISSIONS MADE OB BEHALF OF THE PLAINTIFF:
The Plaintiff is the fifth largest pharmaceutical company in
India, and claims to be the registered proprietor of the mark,
'MANKIND', in all 45 classes, with 78 registrations of
'MANKIND' in various classes. The mark 'MANKIND',
has been certified as a well-known trademark by the Registrar of
Trade Marks and is published in the list of well-known trademarks
maintained by the Registrar. The Plaintiff claims to hold